Literature DB >> 22820944

Overdose of the histamine H₃ inverse agonist pitolisant increases thermal pain thresholds.

Dong Dong Zhang1, Marco Sisignano, Claus Dieter Schuh, Kerstin Sander, Holger Stark, Klaus Scholich.   

Abstract

OBJECTIVE AND
DESIGN: Pitolisant (BF2.649) is a selective inverse agonist for the histamine H(3) receptor and was developed for the treatment of excessive daytime sleepiness in Parkinson disease, narcolepsy, and schizophrenia. Since H(3)-ligands can decrease inflammatory pain, we tested Pitolisant in inflammatory and neuropathic pain models. MATERIALS AND TREATMENTS: Behavioral effects of pitolisant and the structural different H(3) receptor inverse agonists ciproxifan and ST-889 were tested in zymosan-induced inflammation and the spared nerve injury model for neuropathic pain.
METHODS: Responses to mechanical and thermal stimuli were determined. Calcium imaging was performed with primary neuronal cultures of dorsal root ganglions.
RESULTS: Clinically relevant doses of pitolisant (10 mg/kg) had no relevant effect on mechanical or thermal pain thresholds in all animal models. Higher doses (50 mg/kg) dramatically increased thermal but not mechanical pain thresholds. Neither ciproxifan nor ST-889 altered thermal pain thresholds. In peripheral sensory neurons high concentrations of pitolisant (30-500 μM), but not ciproxifan, partially inhibited calcium increases induced by capsaicin, a selective activator of transient receptor potential vanilloid receptor 1 (TRPV1). High doses of pitolisant induced a strong hypothermia.
CONCLUSION: The data show a dramatic effect of high dosages of pitolisant on the thermosensory system, which appears to be H(3) receptor-independent.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22820944     DOI: 10.1007/s00011-012-0528-5

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  45 in total

1.  Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats.

Authors:  Andrew D Medhurst; Michael A Briggs; Gordon Bruton; Andrew R Calver; Iain Chessell; Barry Crook; John B Davis; Robert P Davis; Andrew G Foley; Teresa Heslop; Warren D Hirst; Stephen J Medhurst; Sandrine Ociepka; Alison Ray; Ciaran M Regan; Becky Sargent; Joanne Schogger; Tania O Stean; Brenda K Trail; Neil Upton; Trevor White; Barry Orlek; David M Wilson
Journal:  Biochem Pharmacol       Date:  2007-01-07       Impact factor: 5.858

Review 2.  Transient receptor potential channels as therapeutic targets.

Authors:  Magdalene M Moran; Michael Allen McAlexander; Tamás Bíró; Arpad Szallasi
Journal:  Nat Rev Drug Discov       Date:  2011-08-01       Impact factor: 84.694

3.  Histamine H1, H3 and H4 receptors are involved in pruritus.

Authors:  K Rossbach; C Nassenstein; M Gschwandtner; D Schnell; K Sander; R Seifert; H Stark; M Kietzmann; W Bäumer
Journal:  Neuroscience       Date:  2011-06-13       Impact factor: 3.590

4.  N-methyl-D-aspartate receptor antagonists enhance histamine neuron activity in rodent brain.

Authors:  Raphaël Faucard; Vincent Armand; Anne Héron; Véronique Cochois; Jean-Charles Schwartz; Jean-Michel Arrang
Journal:  J Neurochem       Date:  2006-09       Impact factor: 5.372

5.  Influence of imidazole replacement in different structural classes of histamine H(3)-receptor antagonists.

Authors:  G Meier; J Apelt; U Reichert; S Grassmann; X Ligneau; S Elz; F Leurquin; C R Ganellin; J C Schwartz; W Schunack; H Stark
Journal:  Eur J Pharm Sci       Date:  2001-06       Impact factor: 4.384

Review 6.  Histamine H3 receptor antagonists go to clinics.

Authors:  Kerstin Sander; Tim Kottke; Holger Stark
Journal:  Biol Pharm Bull       Date:  2008-12       Impact factor: 2.233

7.  Novel histamine H3 receptor antagonists GSK189254 and GSK334429 are efficacious in surgically-induced and virally-induced rat models of neuropathic pain.

Authors:  Stephen J Medhurst; Sue D Collins; Andy Billinton; Sharon Bingham; Robert G Dalziel; Amanda Brass; Jennifer C Roberts; Andrew D Medhurst; Iain P Chessell
Journal:  Pain       Date:  2007-12-31       Impact factor: 6.961

8.  Toponomics analysis of drug-induced changes in arachidonic acid-dependent signaling pathways during spinal nociceptive processing.

Authors:  Bona Linke; Sandra Pierre; Ovidiu Coste; Carlo Angioni; Wiebke Becker; Thorsten Jürgen Maier; Dieter Steinhilber; Claus Wittpoth; Gerd Geisslinger; Klaus Scholich
Journal:  J Proteome Res       Date:  2009-10       Impact factor: 4.466

9.  The vanilloid receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation.

Authors:  Narender R Gavva; Anthony W Bannon; Sekhar Surapaneni; David N Hovland; Sonya G Lehto; Anu Gore; Todd Juan; Hong Deng; Bora Han; Lana Klionsky; Rongzhen Kuang; April Le; Rami Tamir; Jue Wang; Brad Youngblood; Dawn Zhu; Mark H Norman; Ella Magal; James J S Treanor; Jean-Claude Louis
Journal:  J Neurosci       Date:  2007-03-28       Impact factor: 6.167

10.  Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor.

Authors:  J M Arrang; M Garbarg; J C Schwartz
Journal:  Nature       Date:  1983-04-28       Impact factor: 49.962

View more
  5 in total

1.  Effects of an H3R antagonist on the animal model of autism induced by prenatal exposure to valproic acid.

Authors:  Diego Baronio; Kamila Castro; Taylor Gonchoroski; Gabriela Mueller de Melo; Gustavo Della Flora Nunes; Victorio Bambini-Junior; Carmem Gottfried; Rudimar Riesgo
Journal:  PLoS One       Date:  2015-01-05       Impact factor: 3.240

2.  Inhibition of histamine receptor 3 suppresses glioblastoma tumor growth, invasion, and epithelial-to-mesenchymal transition.

Authors:  Jia-Ji Lin; Tian-Zhi Zhao; Wen-Ke Cai; Yong-Xiang Yang; Chao Sun; Zhuo Zhang; Yu-Qiao Xu; Ting Chang; Zhu-Yi Li
Journal:  Oncotarget       Date:  2015-07-10

3.  The histamine H3 receptor inverse agonist pitolisant reduces body weight in obese mice.

Authors:  Magdalena Kotańska; Kamil J Kuder; Katarzyna Szczepańska; Jacek Sapa; Katarzyna Kieć-Kononowicz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-05-25       Impact factor: 3.000

Review 4.  Histamine, histamine receptors, and neuropathic pain relief.

Authors:  Ilona Obara; Vsevolod Telezhkin; Ibrahim Alrashdi; Paul L Chazot
Journal:  Br J Pharmacol       Date:  2019-06-07       Impact factor: 8.739

Review 5.  Experimental Drugs for Neuropathic Pain.

Authors:  Kinga Salat; Beata Gryzlo; Katarzyna Kulig
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.